Lv4
530 积分 2025-03-23 加入
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
3天前
已完结
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
3天前
已完结
Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials
3天前
已完结
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
3天前
已完结
Nanoparticles Used for the Delivery of RNAi-Based Therapeutics
11天前
已完结
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment
11天前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
11天前
已完结
LBA5 Updated results from a phase I study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), in combination with toripalimab and chemotherapy as the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA)
11天前
已关闭
Abstract 4805: Dual-target CAR-T strategy for MSLN and CLDN18.2: Advancing cancer treatment with superior efficacy and safety
12天前
已关闭
Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response
1个月前
已完结
皖公网安备34019202002308
